"Medical weight loss" describes who runs a weight programme, not what it contains. The term has no legal definition. It covers a weight clinic in a strip mall, a hospital obesity service and an online subscription, and the bundle each one sells differs: a clinician visit, lab tests, a prescription, coaching, clinic-made injections, or some of these. This page separates the parts, says which are prescription medicines and which are clinic products, sets out the evidence behind each part and the prices three online programmes publish, and says what is not established. It names no programme as better than another.
Read on 16 November 2026 from the US Preventive Services Task Force, the Medicare Coverage Database, and the pricing pages of Found, Calibrate and Noom.
What a programme can include
| Part | What it is | Prescription? | Where the evidence is |
|---|---|---|---|
| Clinician visit | An assessment by a doctor, nurse practitioner or physician assistant, in person or by video or text | — | Required before any prescription; see how a GLP-1 prescription happens |
| Lab tests | Blood tests before or during treatment | — | Often billed separately or to insurance |
| Behavioural programme | Diet, activity and habit coaching, usually many sessions | No | USPSTF review, below |
| Approved weight medicine | Wegovy, Zepbound, Foundayo, the Wegovy pill, Saxenda, Contrave, Qsymia, phentermine, orlistat | Yes | Each drug's label and trials; see weight-loss pills and weight-loss injections |
| Compounded GLP-1 | A pharmacy-made version of semaglutide or tirzepatide | Yes, but not FDA-approved | See compounded GLP-1s |
| Off-label medicine | A drug approved for something else, such as metformin or topiramate | Yes | See metformin and topiramate |
| Clinic shots | B12, "lipo" or "MIC" injections | Usually pharmacy-made; none approved for weight | See lipotropic injections |
| Supplements and meal products | Shakes, bars, fibre capsules sold by the programme | No | See GLP-1 supplements |
The line that matters most is between an approved medicine, which FDA has reviewed for the use on its label, a compounded or off-label medicine, which a clinician can prescribe but which has no approved weight indication in that form, and a clinic product, which is sold as part of the programme without an approval for weight loss at all. The same programme can sell all three.
What the evidence covers, part by part
Behavioural programmes. The US Preventive Services Task Force recommended on 18 September 2018, at grade B, that clinicians "offer or refer adults with a body mass index (BMI) of 30 or higher … to intensive, multicomponent behavioral interventions." Its evidence review pooled 67 trials with 22,065 people: at 12 to 18 months, the programme groups lost 2.39 kg (5.3 lb) more than control groups (95% CI −2.86 to −1.93), with wide variation between trials (I² 90%). Most programmes ran one to two years with 12 or more sessions in the first year. The Task Force notes that FDA treats a 5% weight loss as clinically important.
Medicines. The GLP-1 trials were run on top of counselling: in both arms of STEP 1 and SURMOUNT-1 participants received diet and activity advice. In adults with obesity and no diabetes, semaglutide 2.4 mg lowered weight by 14.9% against 2.4% on placebo over 68 weeks, and tirzepatide 15 mg by 20.9% against 3.1% over 72 weeks. The older medicines and their trial figures are on their own pages: the phentermine label record, Contrave, Qsymia, orlistat.
Clinic shots. For lipotropic, B12 and "MIC" injections sold for weight loss, our census found no approved application for weight and no human trial of the injections for weight; B12 is approved for deficiency. That record is on the lipotropic injections page.
The two sets of figures are not one ranking: the behavioural review measured kilograms against control in mixed adult populations, the drug trials measured percentage of body weight against placebo, with counselling in both arms.
What Medicare pays for
Medicare's National Coverage Determination 210.12, effective for services on or after 29 November 2011, covers intensive behavioural therapy for obesity, defined as a BMI of 30 or higher. It must be given by a qualified primary care practitioner in a primary care setting, and it follows the Task Force's "5-A" counselling framework. The covered schedule:
- one face-to-face visit every week for the first month;
- one every other week for months 2 to 6;
- one a month for months 7 to 12, only if the person has lost at least 3 kg in the first six months, as documented at the six-month reassessment.
That is the counselling part. Whether Medicare or a private plan pays for a weight-loss medicine is a separate rule, covered on does Medicare cover GLP-1s and GLP-1 insurance coverage.
What three online programmes publish as their price
Read from each programme's own pricing page on 16 November 2026. These are membership fees; what they include and leave out is stated as each seller states it.
| Programme | Published price | What the seller says is not included, or costs more |
|---|---|---|
| Found | Cash plans from $149 a month; insurance plans from $79 a month — "based on 12-month plans paid up-front", billed per 28-day cycle. Monthly plans from $269 (cash) or $199 (insurance) | Insurance plans need video visits billed at a copay "typically around $30"; prescriptions at the clinician's discretion; price varies with medicine and coverage. Lists compounded semaglutide and tirzepatide among its medicines |
| Calibrate | $199 a month, "initial 3-month commitment required" — $597 in total | "Lab tests and prescription medications are not included in the membership cost"; GLP-1 copays for most commercially insured members "typically $25/month or less after any deductible is met"; a money-back offer tied to 10% weight loss, on its terms |
| Noom | Microdose GLP-1 Rx programme "starting at $79, regardless of insurance"; access to brand-name medicines "starting at $39 plus any out-of-pocket cost for the medication itself" | Medicine cost depends on insurance; prescriptions need a clinical evaluation |
Three points sit in the small print rather than the headline. The lowest Found prices assume a year paid up front. Calibrate's fee excludes the medicine and the labs, so the total depends on insurance. Noom's $79 programme is a microdose programme; what microdosing a GLP-1 means, and what trials have tested at sub-label doses, is on GLP-1 microdosing. Noom's earlier prices and billing terms are on our Noom cost page. In-person clinic chains publish fewer prices online and were not read for this page; the medicines' own self-pay prices are on GLP-1 cost.
What is not established
- No trial compares one commercial programme with another, so no published evidence says which programme produces more weight loss.
- The behavioural evidence comes from trial programmes with set session counts; whether a given commercial programme delivers that intensity is not shown by its price page.
- The membership prices above do not show what a year of treatment costs once medicines, labs and copays are added; that depends on the medicine and on insurance.
- Whether a programme's clinic products (shots, supplements) add anything to its prescription medicines has not been tested in trials found for this page.
The decision about whether to join a programme, and which medicine if any, belongs with the person and their own clinician, who can weigh their health record, other medicines and insurance. This page reports what programmes sell and what the evidence covers; it does not recommend a programme, a clinic or a medicine.
Sources
- US Preventive Services Task Force, "Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions", final recommendation statement, 18 September 2018 — uspreventiveservicestaskforce.org, read 16 November 2026.
- Centers for Medicare & Medicaid Services, National Coverage Determination 210.12, Intensive Behavioral Therapy for Obesity — Medicare Coverage Database, read 16 November 2026.
- Found, plans and pricing; Calibrate, pricing; Noom Med — read 16 November 2026.
- Wilding JPH et al., NEJM 2021, PMID 33567185 (STEP 1). Jastreboff AM et al., NEJM 2022, PMID 35658024 (SURMOUNT-1).
